Migraine Without Aura — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for migraine without aura. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
1
Active US patents
76/100
Avg vulnerability
—
Annual revenue covered

Originators in Migraine Without Aura

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating migraine without aura. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zavzpret
Zavegepant Hydrochloride
 Pfizer 1 76 — 2031-10-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8481546 Zavzpret method of use 76 2031-10-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8481546 Zavzpret method of use 76 2031-10-07

Related